SCHEMBL4266959

SCHEMBL4266959

O=S(=O)(c1ccccc1)n1c(C(O)c2ccoc2)cc2ccncc21

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RECQL P46063 1/20 0.50
ALDH1A1 P00352 1/20 0.36
LMNA P02545 1/20 0.36
MAPT P10636 1/20 0.36
HTR6 P50406 4/20 0.35
NAMPT P43490 2/20 0.35
PIK3C3 Q8NEB9 2/20 0.34
SRC P12931 1/20 0.34
HDAC3 O15379 3/20 0.33
HDAC4 P56524 3/20 0.33
HDAC1 Q13547 3/20 0.33
HDAC7 Q8WUI4 3/20 0.33
HDAC2 Q92769 3/20 0.33
HDAC10 Q969S8 3/20 0.33
HDAC11 Q96DB2 3/20 0.33
HDAC8 Q9BY41 3/20 0.33
HDAC6 Q9UBN7 3/20 0.33
HDAC9 Q9UKV0 3/20 0.33
HDAC5 Q9UQL6 3/20 0.33
JAK2 O60674 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4271243 0.88 RECQL (0.57) RECQLALDH1A1LMNAMAPTHTR6
SCHEMBL4276540 0.87 RECQL (0.56) RECQLALDH1A1LMNAMAPTHTR6
SCHEMBL4275790 0.81 RECQL (0.50) RECQLALDH1A1LMNAMAPTHTR6
SCHEMBL20417734 0.77 RECQL (0.68) RECQLALDH1A1LMNAMAPTHTR6
SCHEMBL4279643 0.73 RECQL (0.43) RECQLALDH1A1LMNAMAPTHTR6
SCHEMBL22122381 0.72 RECQL (0.50) RECQLALDH1A1LMNAMAPTNAMPT
SCHEMBL5833331 0.72 RECQL (0.43) RECQLALDH1A1LMNAMAPTHTR6
SCHEMBL21115189 0.71 HTR6 (0.44) RECQLALDH1A1LMNAMAPTHTR6
SCHEMBL5833077 0.71 PPARG (0.44) RECQLALDH1A1LMNAMAPTHTR6
SCHEMBL6864332 0.71 RECQL (0.73) RECQLALDH1A1LMNAMAPTHTR6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7608627-B2 I kappa B kinase inhibition; diabetes; (7-Chloro-1H-pyrrolo[2,3-c]pyridin-2-yl)methanol; N-Benzyl-7-chloro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-27 US disclosed
US-20080064715-A1 6-Azaindole Compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-03-13 US disclosed
EP-1732566-A2 6-AZAINDOLE COMPOUND Takeda Pharmaceutical Company Limited (JP) 2006-12-20 EP disclosed
WO-2005097129-A2 6-AZAINDOLE COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2005-10-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080064715-A1 6-Azaindole Compound RELA, NFKBIA, GPR119 RECQL 1543/4885ALDH1A1 3508/4885LMNA 3936/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.